GLP-1 Meds May Help Extremely Obese Qualify for Weight-Loss Surgery
Medically reviewed by Drugs.com.
By Dennis Thompson HealthDay Reporter
FRIDAY, June 14, 2024 -- Taking a cutting-edge weight-loss drug could help extremely obese patients drop enough pounds to be eligible for bariatric surgery, a new study shows.
Patients with extreme obesity -- a BMI of 70 or more -- are at higher risk of complications from surgery compared to people who weigh less.
Weight loss prior to surgery can lower that risk, but up to now nothing’s been able to help patients lose enough weight to make a difference, researchers say.
However, new GLP-1 agonist medications like Ozempic, Wegovy and Zepbound have been shown to help people quickly shed pounds.
For this trial, researchers recruited 113 extremely obese patients and assigned them to either a single GLP-1 drug, more than one GLP-1 drug or a medically supervised diet and exercise program. Patients were treated an average of 73 days.
People on multiple drugs had the greatest weight loss, dropping about 13% of their total body weight.
A single GLP-1 drug helped people lose a little more than 8% of their body weight, while diet and exercise helped participants drop about 6% of their body weight.
The findings were presented Thursday at the American Society for Metabolic and Bariatric Surgery’s annual meeting in San Diego.
“Combining anti-obesity medications may achieve much greater pre-surgery weight loss than other methods for those with extreme obesity,” said researcher Dr. Phil Schauer, director of the Metamor Metabolic Institute at Pennington Biomedical in Baton Rouge, La. “Many patients who would otherwise be considered ‘too sick for surgery’ may now qualify.”
More than 42% of Americans are obese, researchers said in background notes.
GLP-1 drugs work by mimicking a hormone in the body that controls insulin release and acts to reduce hunger and delay stomach emptying.
“More studies are needed to determine the optimal role of GLP-1s before and after metabolic and bariatric surgery among different patient groups,” Dr. Marina Kurian, president of the American Society for Metabolic and Bariatric Surgery, said in a meeting news release.
“Obesity must be viewed like other chronic diseases, where sometimes more than one therapy is necessary over time and for different reasons,” added Kurian, who was not involved in the study.
Because this research was presented at a medical meeting, it should be considered preliminary until published in a peer-reviewed journal.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-06-14 23:15
Read more
- IDSA: Vaccination Less Likely With Increasing Social Vulnerability, Black Race
- Ozempic, Wegovy Might Help Lower Alzheimer's Risk in People With Diabetes
- ACAAI: Most Syphilis Patients With Penicillin Allergy Have Low Risk for Severe Allergy
- ASN: Empagliflozin Offers Lasting Cardiorenal Benefit in CKD Patients
- Risk for Psychiatric Disorders Up for Offspring of Moms With Eating Disorder
- American College of Allergy, Asthma & Immunology, Oct. 24-28
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions